
Carlos Torrado
@CarlosTorradoMD
Followers
297
Following
47
Media
25
Statuses
138
Medical Oncologist 🇪🇸🇪🇺 Clinical Fellow at MD Anderson Cancer Center 🇺🇸 Investigational Cancer Therapeutics (A Phase I Program). PGY-7
Houston, TX
Joined November 2021
RT @MadhuEluri: @CarlosTorradoMD Congrats!! I know we never met but shared many patients and they were very grateful you took such great ca….
0
1
0
RT @AnishJayJain: Congratulations my friend!!! Excited for all the great things you’ll go and hope to see you soon in Houston or California….
0
1
0
RT @mgoudaMD: Effective today, I am starting a new role as an Assistant Professor of Medical Oncology at MD Anderson Cancer Center. My prim….
0
11
0
RT @mgoudaMD: Back in Houston after an incredible week at ASCO/AACR #MCCR25!.Truly honored to be part of the 2025 class of the #VailWorksho….
0
1
0
RT @AminaChaudhryMD: Such an incredible week in San Diego learning clinical trial design! Grateful to connect with these innovators as we w….
0
3
0
RT @RyanDenu: Today is my first clinic as attending physician at @MDAndersonNews .#endcancer #sarcoma
0
8
0
Huge congratulations! So well deserved!.
#JIPO received its 1st official #impactfactor = 3.2! .Immunology/Oncology Rank: Q2/Q3. We thank everyone who contributed to this achievement!.@ANaingMD @InnoJournals @OncologyNetwork @jibranahmed1 @MekhailYN @mderbalamd @HafezMaria @CarlosTorradoMD @SewantiLimaye @weoncologists
0
0
3
RT @jmacylawrence: ICT fellow’s farewell dinner (but all 3 leaving will be joining as faculty @MDAndersonNews )! 👏👍🥳 @CamilaBragancaX @Carl….
0
2
0
RT @CamilaBragancaX: Our lovely pic w/ the amazing @MDAndersonNews ICT APPs ⭐️ Thank you for your friendship & support during our Fellowshi….
0
3
0
RT @MDAndersonNews: “The heterogeneity of sarcomas coupled with their rarity makes them hard to study, and conflicting results from studies….
0
2
0
RT @CamilaBragancaX: Amazing #ASCO25 with the (former & current) ICT team!! @MDAndersonNews @haroldnathantan @CarlosTorradoMD @mgoudaMD @Da….
0
5
0
RT @MDAndersonNews: HMPL-306, a novel small-molecular dual inhibitor of IDH1 and IDH2 mutations is safe and well tolerated and showed durab….
0
3
0
RT @MDAndersonNews: Presented by Dr. Tim Yap at #ASCO25: BNT142, a bispecific antibody therapy, shows manageable safety and early anti-tumo….
0
8
0
RT @JIPOEditors: @ANaingMD and @doctorpemm.More to come at #ASCO2025 #ASCO25 #ASCO #JIPO . @MekhailYN @mderbalamd @HafezMaria @CarlosTorrad….
0
2
0
RT @DavidHongMD: What an amazing night at the @MDAndersonNews 2025 Faculty honors convocation! Our own Tim Yap aka Taylor Swift took home….
0
6
0